At PEGS EU 2021, Abveris CEO Tracey Mullen shared a few important lessons learned through using the Beacon system for antibody discovery. She discussed how the Berkeley Lights Platform has enabled Abveris to focus on deeply screening their antibodies upstream and only pulling forward the most qualified and functionally relevant antibodies for re-expression.

Please fill out the following form to access this resource:

First Name*
Last Name*
Email Address*
Phone Number*
City*
Country*
State*
Company/Institute*
CAPTCHA

Related Resources

View All Resources

Antibody Discovery

Application Note: Rapid Discovery of Therapeutic Antibodies for the SARS-CoV-2 Pandemic Virus Using the Opto Viral Neutralization 1.0 Workflow

Learn how to use blocking and binding assays and the Opto Viral Neutralization 1.0 workflow to identify cross-reactive antibodies that may have broad neutralization capacity across the coronavirus family.

Antibody Discovery

Webinar: Accelerating Antibody Discovery in the Modern Therapeutic Landscape

Learn how antibody discovery is changing in today’s therapeutic space. Case studies presented by Abveris highlight accelerated development of next-generation antibody therapeutics.

Antibody Discovery

App Note: Discover Lead Molecules Against Difficult Targets Inaccessible by Hybridoma Methods

Download this application note to learn about how the Opto™ Plasma B Discovery workflow increases hit recovery for difficult membrane-bound targets and provides access to greater sequence diversity when compared to traditional hybridoma methods.